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Introduction. Hematological indices including red cell distribution width and neutrophil to lymphocyte ratio are proven to be
associated with outcomes of acute coronary syndrome. The usefulness of machine learning techniques in predicting mortality
after acute coronary syndrome based on such features has not been studied before. Objective. We aim to create an alternative
risk assessment tool, which is based on easily obtainable features, including hematological indices and inﬂammation markers.
Patients and Methods. We obtained the study data from the electronic medical records of 5053 patients hospitalized with acute
coronary syndrome during a 5-year period. The time of follow-up ranged from 12 to 72 months. A machine learning classiﬁer
was trained to predict death during hospitalization and within 180 and 365 days from admission. Our method was compared
with the Global Registry of Acute Coronary Events (GRACE) Score 2.0 on a test dataset. Results. For in-hospital mortality, our
model achieved a c-statistic of 0.89 while the GRACE score 2.0 achieved 0.90. For six-month mortality, the results of our
model and the GRACE score on the test set were 0.77 and 0.73, respectively. Red cell distribution width (HR 1.23; 95%
CL 1.16-1.30; P < 0 001) and neutrophil to lymphocyte ratio (HR 1.08; 95% CL 1.05-1.10; P < 0 001) showed independent
association with all-cause mortality in multivariable Cox regression. Conclusions. Hematological markers, such as neutrophil
count and red cell distribution width have a strong association with all-cause mortality after acute coronary syndrome. A
machine-learned model which uses the abovementioned parameters can provide long-term predictions of accuracy
comparable or superior to well-validated risk scores.
1. Introduction
The term acute coronary syndrome (ACS) refers to many
conditions which include non-ST-segment elevation acute
coronary syndrome (NSTE-ACS) and ST-elevation myo-
cardial infarction (STEMI). The common cause of these
conditions is inadequate blood ﬂow to the myocardium
which can be related to acute cholesterol plaque rupture
or erosion and thrombus formation. These conditions have
a similar presentation, and the most frequent symptom
reported by patients is chest pain, which is one of the
most common causes of presentation to the emergency
room accounting for up to 6% of emergency department
attendances and 27% of medical admissions [1]. Current
guidelines emphasize the usefulness of established quanti-
tative risk scores for prognosis estimation [2], which is
necessary for the adequate and cost-eﬀective provision of
evidence-based therapies.
An increased systemic and local inﬂammation plays a
crucial role in the pathophysiology of ACS. Various hema-
tological indices have been reported to be associated with
poorer prognosis or the occurrence of major adverse car-
diac events after ACS [3]. These indices include neutrophil
to lymphocyte ratio (NLR) [4–6], platelet to lymphocyte
ratio (PLR) [7], red cell distribution width (RDW) [8], and
mean platelet volume (MPV). These studies brought evi-
dence that such nonspeciﬁc markers of the inﬂammatory
response are associated with the GRACE score. [9] Moreover,
they can improve its discriminative capabilities [10, 11].
Machine learning (ML) is a ﬁeld of computer science that
uses various computational algorithms to give computer
systems the ability to progressively improve performance
on a speciﬁc task with data, without being explicitly pro-
grammed. This term describes a vast spectrum of computa-
tional methods, many of which like logistic regression have
been used extensively in medical sciences for many years
[12]. The most state-of-the-art algorithms are currently
subject of intense research and have been recently shown
to perform on par with trained ophthalmologists in detect-
ing diabetic retinopathy in eye fundus images [13], classify
skin lesion images automatically with dermatologist-level
accuracy [14], or detect hip fractures from frontal pelvic
X-rays [15].
In our previous research, we successfully used ML tech-
niques to predict in-hospital mortality [16]. In this study,
we attempt to develop a new tool for long-term risk assess-
ment following ACS and compare its performance with the
GRACE 2.0 model. In contrast to existing risk scores, our tool
relies on laboratory tests (including hematological indices)
and simple measurements (including blood pressure and
heart rate), rather than clinical features. The rationale for
such approach is the proven association of inﬂammatory
response with ACS outcomes.
2. Methods
We retrospectively examined electronic medical records of
patients admitted to a cardiology department between Janu-
ary 2012 and December 2016 to select all patients hospital-
ized because of an ACS. The analyzed group comprised of
patients who had their diagnosis conﬁrmed by a cardiologist
according to ESC guidelines [2].
5053 individual patients were qualiﬁed (1522 with
STEMI, 857 with NSTEMI, and 2674 with unstable angina).
We analyzed the descriptions of the electrocardiograms in
the patient’s medical records to identify patients who had
an ST-segment elevation (n = 1522) or any ST-segment
deviation-elevation or depression (n = 4420) according to
current guidelines.
We obtained information on all-cause death or survival
and on the exact date of death from the national death regis-
try one year after the end of data collection. Patients who had
incomplete records or had no blood sample taken during
hospitalization were excluded from the study. If a patient
was admitted with ACS more than one time in the analyzed
period, only the last hospitalization was considered.
All patients were treated according to current
guidelines and doctor’s therapeutic decisions. Each patient
had a venous blood sample taken within 30 minutes from
admission. The complete blood count and hematological
parameters were analyzed using an automated blood cell
counter CD-RUBY (Abbott, Lake Bluﬀ, Illinois, USA). Bio-
chemical parameters were measured using COBAS 6000
Table 1: Variables used in the Cox regression model, machine-learned model, and for the calculation of the GRACE score.
COX regression Machine-learned model GRACE score
n = 4743 (310 observations excluded due to missing values) n = 4969 (84 observations excluded due to missing values that where
required to calculate GRACE score)
Troponin elevation ratio Troponin elevation ratio Age
Neutrophil to lymphocyte ratio
Platelet to lymphocyte ratio
Red cell distribution width Heart rate
Red cell distribution width Platelet count Systolic blood pressure
Platelet count Creatinine level Creatinine level
Creatinine level Hemoglobin level ST-segment deviation
Fibrinogen level Mean cell volume Troponin elevation (true or false)
Hemoglobin level Sodium level Killip class
Potassium level Prothrombin time
Mean cell volume Fibrinogen level
Monocyte count Age
Sodium level Lymphocyte count
Prothrombin level Neutrophil count
Age LDL level
Heart rate at admission CRP level
Systolic blood pressure Sex
ST-segment elevation Heart rate
Diabetes Systolic blood pressure
Diastolic blood pressure
Body mass index
LDL: low-density lipoprotein; CRP: C-reactive protein.
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(Roche, Basel, Switzerland). The results of the laboratory
tests as well as the clinical information were obtained ret-
rospectively from the electronic medical record (EMR) sys-
tem at the time of follow-up. During the period of data
collection, both Troponin I and Troponin T were used.
Therefore, we expressed troponin elevation as a ratio (actual
value divided by the norm).
Statistical analyses were performed using the RStudio
Software. The Shapiro-Wilk test was used to test the
variables’ distribution for normality. Most of the analyzed
variables did not have a normal distribution. Median and
interquartile ranges were selected as measures of central
tendency. The univariable two-tailed Mann-Whitney U test
was used to compare numerical features. We created a mul-
tivariable Cox regression model using variables with statisti-
cally signiﬁcant diﬀerences (P value <0.05) in univariate
analysis. 310 observations were excluded from the analysis
because of missing values. We did not use automated
stepwise backward elimination. Instead, all variables which
were suspected to inﬂuence the outcome were entered into
the model [17]. The list of variables used in the Cox
regression model is presented in Table 1. The proportional
hazard assumption was veriﬁed using Schoenfeld residuals.
To assess the time-varying eﬀects of the selected variables,
Aalen’s additive model was used. A P value <0.05 indicated
statistical signiﬁcance. The results were presented as hazard
ratios with 95% conﬁdence intervals (CI).
A probability of death during hospitalization and after 6
and 12 months from admission according to the GRACE 2.0
score was calculated using the model coeﬃcients published
on the GRACE project website (https://www.outcomes-
umassmed.org/grace/). A Python package was developed to
allow for the batch calculation of the GRACE 2.0 death prob-
ability based on relevant clinical and laboratory features. As
the information about Killip class and creatinine level was
available for almost all patients, the full version of the
Table 2: Baseline characteristics according to the survival or death status–numerical variables. Data is presented as median and interquartile
range (IQR). P values refer to the results of the two-tailed Mann-Whitney U test.
Survival (n = 4287) Death (n = 766) P value
Age (years) 65.5 (59.4-73.0) 72.1 (64.4-79.8) <0.001
Troponin elevation (ratio) 0.9 (0.4-3.9) 3.1 (0.7-38.2) <0.001
Systolic blood pressure (mmHg) 120.0 (110.0-130.0) 117.0 (110.0-130.0) <0.001
Diastolic blood pressure (mmHg) 80.0 (75.0-90.0) 78.0 (70.0-85.0) <0.001
Heart rate at admission 72.0 (64.0-83.0) 76.0 (66.0-89.0) <0.001
C-reactive protein (mg/dl) 0.4 (0.2-1.8) 2.2 (0.6-6.4) <0.001
Fibrinogen (mg/dl) 398.0 (344.0-467.0) 430.0 (363.8-517.2) <0.001
Creatinine (mg/dl) 1.0 (0.8-1.1) 1.1 (0.9-1.4) <0.001
Neutrophil (103/mm3) 5.1 (3.9-6.6) 6.1 (4.5-8.6) <0.001
Lymphocyte (103/mm3) 1.9 (1.5-2.4) 1.6 (1.2-2.2) <0.001
Monocyte (103/mm3) 0.6 (0.5-0.7) 0.7 (0.5-0.9) <0.001
Eosinophil (103/mm3) 0.1 (0.1-0.2) 0.1 (0.0-0.2) <0.001
Hematocrit (%) 42.7 (39.8-45.4) 40.3 (35.9-43.9) <0.001
Hemoglobin (g/dl) 14.5 (13.5-15.5) 13.5 (11.9-14.8) <0.001
Red cell distribution width 12.2 (11.6-12.9) 12.8 (12.0-14.0) <0.001
Mean cell volume (ﬂ) 91.1 (88.2-94.4) 91.6 (88.1-95.2) 0.1
Platelets (103/mm3) 221.0 (186.0-261.0) 223.0 (174.2-269.0) 0.72
Mean platelet volume (ﬂ) 8.6 (7.5-9.8) 8.3 (7.3-9.6) 0.001
Alanine aminotransferase (U/l) 24.0 (17.0-34.0) 23.0 (16.0-37.0) 0.01
Aspartate aminotransferase (U/s) 24.0 (19.0-32.0) 28.0 (20.0-52.0) <0.001
Basophil count (103/mm3) 0.1 (0.1-0.1) 0.1 (0.0-0.1) 0.02
Cholesterol level (mg/dl) 175.0 (144.0-216.0) 162.0 (135.0-198.0) <0.001
Low-density lipoprotein (mg/dl) 106.0 (78.0-143.0) 97.0 (73.0-127.0) <0.001
High-density lipoprotein (mg/dl) 50.0 (41.0-60.0) 46.0 (37.0-57.0) <0.001
Triglycerides (mg/dl) 122.0 (88.0-172.0) 105.0 (79.8-149.2) 0.04
Sodium (mmol/l) 141.0 (139.0-143.0) 140.0 (138.0-142.0) <0.001
Potassium (mmol/l) 4.4 (4.1-4.7) 4.4 (4.1-4.8) 0.01
Urea (mg/dl) 36.0 (30.0-45.0) 47.0 (36.0-65.2) 0.4
Neutrophil to lymphocyte ratio 2.6 (1.9-3.7) 3.6 (2.4-5.9) <0.001
Platelet to lymphocyte ratio 114.4 (87.8-149.6) 131.6 (94.4-187.3) <0.001
Days of hospitalization 4.0 (3.0-5.0) 4.0 (3.0-7.0) <0.001
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algorithmwas used. In 84 cases themissing data did not allow
for the calculation of theGRACE probability. Table 1 presents
and compares the variables analyzed in the COX regression
model as well as the variables used by the ML model and for
the calculation of the GRACE score.
2.1. Machine Learning Methods. Model selection, optimiza-
tion, and ﬁtting were performed using the Python 3.6 and
scikit-learn software packages. We used 4969 observations
for training and evaluating the ML model. We have excluded
84 observations where variables necessary to calculate the
GRACE score were missing, as presented in Table 1. The
remaining missing values which did not aﬀect the calculation
of the GRACE score were imputed using mean of all observa-
tions. The gradient-boosted tree algorithm was implemented
using the xgboost [18] software package.
One-ﬁfth of the available data (n = 994) was put aside as a
test set and not used for training. Observations for the test set
were chosen randomly, but in a way that preserved the ratio
of positive to negative class (death and survival). The ML
classiﬁer was optimized using the training data only
(n = 3975), using the 5-fold cross-validation. In this process,
the training data was divided into 5 parts, and each of these
parts was used to train the classiﬁer and to measure its per-
formance. We measured the performance of the GRACE
score and our model by calculating the areas under Receiver
Operating Characteristic (ROC) curves. The performance
measurements during cross-validation were averaged and
expressed by mean ± standard deviation. Finally, the perfor-
mance of both classiﬁers was compared by calculating the
areas under the ROC curves on the test set which was not
used for training the ML model at all. This process was
repeated in identical fashion for all analyzed endpoints:
in-hospital death, 6-month death, and 12-month death.
3. Results
The in-hospital mortality rate was 1.64% (n = 83) within 6
months from admission 5.87% (n = 297) and within a year
from admission 7.85% (n = 397). 766 patients (15%) died
during the period of the study (from January 2012 until
acquisition of the survival data in December 2017). The base-
line clinical characteristics and laboratory test results accord-
ing to survival status are presented in Tables 2 and 3. Some
variables including the presence of ST-segment elevation,
troponin elevation, sodium levels, and systolic blood pressure
did not meet the proportional hazard assumption. However,
examining Aalen’s additive model indicated that these
parameters have a high prognostic value shortly after admis-
sion that decreases over time. The results of the multivariable
Cox regression analysis are visualized in the form of a forest
plot on Figure 1. High RDW, NLR, monocyte count, creati-
nine level, prothrombin time, age, and heart rate as well as
low sodium and hemoglobin were signiﬁcantly associated
with all-cause mortality in the multivariable model. Due to
a large number of missing values for CRP and LDL levels,
they were not considered for survival analysis, but we kept
them in the machine-learned model because of their known
association with ACS pathophysiology and outcomes [19].
3.1. Machine Learning Results. The model based on the
gradient-boosted trees was trained using the following vari-
ables as input: troponin elevation ratio, NLR, PLR, RDW,
CRP, platelet count, creatinine, hemoglobin, mean cell vol-
ume, sodium, prothrombin time, ﬁbrinogen, age, neutrophil
count, body mass index, systolic and diastolic blood pressure,
heart rate, and sex. The variables were selected to maximize
the model’s performance, but clinical parameters including
the data from the patient’s medical history and physical
examination were not included in the model. The point was
to create a model that could use data that is routinely col-
lected in the EMR system for all patients. The model’s perfor-
mance metrics are summarized in Table 4. Figure 2 presents
the Receiver Operating Characteristic curves for our classiﬁer
and the GRACE score 2.0 for the detection of in-hospital,
6-month, and one-year mortality. Eyeballing the Receiver
Operating Characteristic (ROC) curves and analysis of areas
under these curves (AUROC) reveal that the results of our
model and the GRACE score 2.0 are similar. GRACE per-
formed slightly better for short-term results (AUROC 0.9
vs. 0.89) while our model scored better in long-term results
(AUROC 0.77 vs. 0.73 and 0.72 vs. 0.71 for 6-month and
one-year mortality, respectively).
4. Discussion
The results of the survival analysis using Cox regression con-
ﬁrm ﬁndings from numerous studies regarding the associa-
tion of hematological indices including RDW, NLR, and
Table 3: Baseline characteristics according to the survival or death
status–categorical variables.
Survival (n = 4287) Death (n = 766)
Sex
Male 2908 493
Female 1379 273
Diabetes
No diabetes 3106 503
Type 1 diabetes 20 2
Type 2 diabetes 1161 261
PCI during hospitalization
True 2565 468
False 1722 298
Killip Class
I 4196 708
II 74 24
III 9 9
IV 8 25
ST-segment elevation
False 3047 484
True 1240 282
ST-segment deviation
False 3521 699
True 766 67
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neutrophil count with short- and long-term prognosis after
acute coronary syndrome [3]. The low-grade inﬂammatory
process plays an important role in the formation and subse-
quent destabilization and rupture of the atherosclerotic pla-
que [20]. In the multivariable Cox regression model, RDW
had a strong association with all-cause mortality (HR 1.22,
95% Cl 1.17-1.28). These results are consistent with the
ﬁndings from other studies that identiﬁed RDW as a prog-
nostic marker in cardiovascular diseases and heart failure
[21] and also as a predictor of all-cause mortality [22]. It
was suggested that patients with increased RDW have lower
oxygen supply at tissue level due to decreased red blood cell
deformability and impaired blood ﬂow through microcircu-
lation [23]. Our results also seem to conﬁrm the ﬁndings
Hazzard ratio
(95% Cl)
Troponin elevation (ratio)
Neutrophil to lymphocytes ratio
Platelet to lymphocytes ratio
Red cells distribution width
Platelet count
Creatinine
Fibrinogen
Hemoglobin
Potassium
Mean cell volume
Monocytes count
Sodium
Prothrombin time
Age
Heart rate
Systolic blood pressure
ST-segment elevation
Diabetes
1 1.2 1.4 1.6 1.8
1.14
(0.97 - 1.34)
1.19
(1.01 - 1.41)
0.99
(0.99 - 0.99)
1.01
(1.00 - 1.01)
1.05
(1.04 - 1.05)
1.02
(1.01 - 1.03)
0.95
(0.93 - 0.97)
1.42
(1.12 - 1.81)
1.02
(1.01 - 1.04)
1.13
(0.98 - 1.31)
0.91
(0.87 - 0.95)
1.00
(1.00 - 1.00)
1.17
(1.10 - 1.24)
1.00
(1.00 - 1.00)
1.22
(1.17 - 1.28)
1.00
(1.00 - 1.00)
1.06
(1.04 - 1.08)
1.00
(1.00 - 1.00)
0.114 
0.04⁎
<0.001⁎⁎⁎
0.004⁎⁎
<0.001⁎⁎⁎
0.003⁎⁎
<0.001⁎⁎⁎
0.004⁎⁎
<0.001⁎⁎⁎
0.093 
<0.001⁎⁎⁎
<0.001⁎⁎⁎
<0.001⁎⁎⁎
0.761 
<0.001⁎⁎⁎
0.377 
<0.001⁎⁎⁎
0.405 
Pvalue
Figure 1: Results of Cox regression. Hazard ratios are presented as black rectangles, and conﬁdence level bands are presented as whiskers. The
central vertical line indicates a hazard ratio of 1.
Table 4: Performance of classiﬁers in predicting death during hospitalization, within 6 months, and one year after admission.
In-hospital mortality 6-month mortality One-year mortality
Our algorithm on validation set 0 85 ± 0 04 0 78 ± 0 03 0 78 ± 0 03
GRACE 2.0 on validation set 0 89 ± 0 04 0 77 ± 0 03 0 76 ± 0 03
Our algorithm on test set 0.89 0.77 0.72
GRACE 2.0 on test set 0.90 0.73 0.71
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from other studies [24] on the impact of admission anemia
on long-term prognosis in ACS.
Our model performed better than GRACE score for
medium- and long-term prognosis. However, the diﬀerence
in performance was small, and the calculations of the
GRACE scores in our study were made based on retrospec-
tive data and could be inaccurate in some cases. This result
needs to be conﬁrmed in prospective validation. Better
long-term performance of our model might be related to
the fact that it uses inﬂammation biomarkers. The underly-
ing inﬂammation process is known to be related to athero-
sclerosis, but the currently used risk scores do not take
advantage of this fact.
GRACE score 2.0 has been extensively validated in vari-
ous populations and proved to have superior discriminatory
accuracy for predicting major adverse cardiac events when
compared to other risk assessment tools [25, 26]. However,
the adoption of its use in a clinical setting was reported to
be unsatisfactory. One of the reasons for such situation is
the necessity of use of an external application which requires
manual data input and consumes extra time [27]. Studies
have shown that the integration of risk assessment scores into
IT solutions resulted in higher compliance [28]. With all the
necessary data available in the electronic medical record sys-
tem, after integration into existing software, our solution can
provide risk assessment without any additional input from
the physician. The result could then trigger relevant alerts,
helping to select the highest risk patients.
Several studies investigated the application of machine
learning techniques to risk stratiﬁcation in ACS. Most of
these studies used data collected retrospectively from a large
number of electronic medical reports, similarly as we did in
our study [29, 30]. The models they created, however, were
based on numerous clinical features, and it is diﬃcult to
reproduce the results and apply their solution in a diﬀerent
setting. For instance, VanHouten et al. reported that their
machine-learned model could outperform the GRACE score.
They used numerous sparse features including the full blood
count in most patients and their classiﬁer achieved area
under receiver operating curve of 0.85. Our model yields
comparable performance, but thanks to using the smaller
number of free-of-interpretation features, it is easier to apply
and validate externally.
5. Study Limitations
In our study, we retrospectively analyzed the electronic med-
ical records of patients hospitalized over several years. This
allowed for rapid development on an ML algorithm but is
also a signiﬁcant limitation.
Data stored in medical records are often incomplete,
complex, messy, and can be biased [31]. The naive use of
raw medical records as input for either inferential statistics
or machine learning models can lead to false conclusions. A
good example of such situation is the study of Fine et al., in
which patients who were admitted with severe community-
acquired pneumonia and died in the emergency department
had very little information stored in medical records. As a
result, some deceased patients appeared healthier than those
who survived [32].
The most concerning limitation of our study is related to
variables that were stored in medical records as unstructured
data in the form of physicians’ notes (e.g., descriptions of
electrocardiograms). When designing our classiﬁer, we only
intended to use features that are available in the medical
records as single measurements. Clinical features, including
the results of physical examination, patient’s symptoms,
and medical history, were not considered. This approach is
diﬀerent than those proposed by many other studies
exploring the application of machine learning methods in
predicting ACS outcomes [29, 30], where all the features that
were available in EMR were used. Nevertheless, determining
the presence of ST-segment deviation was necessary for
calculating the GRACE score. We did not analyze the
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Figure 2: (a), (b), and (c) represent Receiver Operating Characteristic (ROC) curves for in-hospital mortality, 6-month mortality, and
one-year mortality, respectively. ROC curves for our classiﬁer are drawn using a blue line, while ROC curves for the Global Registry of
Acute Coronary Events (GRACE) 2.0 score are drawn using an orange line.
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electrocardiograms directly, and the classiﬁcation of some
ECG descriptions was not obvious. Therefore, the calcula-
tions of the GRACE score were especially prone to bias. To
make a justiﬁed statement on the performance of our classi-
ﬁer vs. any other existing score, it is necessary to evaluate it
prospectively, and the scores should be calculated on the
day of admission to the hospital.
The follow-up in our study was limited to death or sur-
vival status. This is also an important limitation because it
was not possible to assess the occurrence of major adverse
cardiac events other than all-cause death. Many patients
suﬀered from recurrent ACS, which we did not analyze in
this study. Instead, we only took into account the last avail-
able hospitalization.
Another important limitation is related to using the Cox
regression model. Some of the variables which we used in this
model did not meet the proportional hazard assumption.
Nevertheless, after analyzing diﬀerent regression models,
we concluded that the predictive value of ST-segment eleva-
tion, troponin elevation, sodium levels, and systolic blood
pressure may decrease over time and that it is worth present-
ing the results in this form.
Finally, although the study included patients hospital-
ized over many years, this dataset is still modest in terms
of machine learning model development. The performance
of our classiﬁer varied slightly, depending on which obser-
vations were chosen randomly for the test set. In contrast,
GRACE score was validated on over 100000 patients
worldwide, thus the evidence that supports its usefulness
is strong. We do not aim to prove that our method is bet-
ter than any existing well-validated risk score, but to pres-
ent a new approach to long-term risk prediction in ACS
based on diﬀerent analytic methods and diﬀerent variables
than existing scores.
6. Conclusions
Hematological markers of inﬂammation show strong corre-
lation with the outcomes of ACS, and they can be successfully
incorporated into numerical models designed to support
clinical decisions. Our model predicted long-term mortality
better than GRACE score, but the diﬀerence might not be sig-
niﬁcant, and it requires prospective validation. The potential
of such solution lies in taking advantage of the easily available
hematological biomarkers and in eliminating the necessity to
enter the results of clinical examination or the past medical
history into the model.
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